James D. Winkler
Plus aucun poste en cours
Profil
James D.
Winkler served as Director of Oncology Research at GlaxoSmithKline Australia Pty Ltd.
and Vice President of Discovery & Translational Biology at Array BioPharma, Inc. He also served as Chief Scientific Officer at Arvinas Operations, Inc. and Vice President of Business Development at Prescient Therapeutics Ltd.
Winkler holds a doctorate from the University of Pennsylvania and an undergraduate degree from Princeton University.
Anciens postes connus de James D. Winkler
| Sociétés | Poste | Fin |
|---|---|---|
Glaxosmithkline Australia Pty Ltd.
 Glaxosmithkline Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Glaxosmithkline Australia Pty Ltd. manufactures and markets prescription medicines, prescribed vaccines, and consumer healthcare products. It serves healthcare professionals and consumers. The company was founded in 1886 and is headquartered in Melbourne, Australia. | Corporate Officer/Principal | - |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Directeur Technique/Scientifique/R&D | - |
| PRESCIENT THERAPEUTICS LIMITED | Corporate Officer/Principal | - |
| ARRAY TECHNOLOGIES, INC. | Corporate Officer/Principal | - |
Formation de James D. Winkler
| Princeton University | Undergraduate Degree |
| University of Pennsylvania | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PRESCIENT THERAPEUTICS LIMITED | Health Technology |
| Entreprise privées | 3 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Health Technology |
Glaxosmithkline Australia Pty Ltd.
Glaxosmithkline Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Glaxosmithkline Australia Pty Ltd. manufactures and markets prescription medicines, prescribed vaccines, and consumer healthcare products. It serves healthcare professionals and consumers. The company was founded in 1886 and is headquartered in Melbourne, Australia. | Health Technology |